黄葵胶囊联合雷公藤多苷片治疗糖尿病肾病的临床观察

Clinical Observation of Abelmoschus moschatus Capsule Combined with Tripterygium Glycosides Tablets in the Treatment of Diabetic Nephropathy

目的:观察黄葵胶囊联合雷公藤多苷片治疗糖尿病肾病(DN)的临床疗效及安全性。方法:将136例DN患者随机均分为试验组和对照组,在给予糖尿病基础治疗的同时,试验组患者给予黄葵胶囊5粒,口服,3次/d,并给予雷公藤多苷片20 mg,口服,3次/d;对照组患者仅给予雷公藤多苷片20 mg,口服,3次/d。两组患者疗程均为12周。观察患者治疗的总有效率及肾功能、血脂、血糖、氧化应激指标的改善及不良反应情况。结果:治疗后试验组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.05);试验组患者治疗后肾功能、血脂、血糖、氧化应激指标的改善均显著优于对照组,两组比较差异有统计学意义(P<0.05或P<0.01)。所有患者不良反应均可耐受,未见严重不良反应发生。结论:黄葵胶囊联合雷公藤多苷片较单用雷公藤多苷片治疗DN疗效更显著,且安全性较好。

OBJECTIVE：To observe the clinical efficacy and safety of Abelmoschus moschatus capsule combined with Tripterygium glycosides tablets in the treatment of diabetic nephropathy（DN）. METHODS：136 DN patients were randomly divided into experimental group and control group. Based on diabetes mellitus routine therapy,experimental group was additionally given 5 pieces of A. moschatus capsule orally,3 times a day and Tripterygium glycosides tablets 20 mg orally,3 times a day;control group was additionally given Tripterygium glycosides tablets only 20 mg orally,3 times a day. Treatment courses of 2 groups lasted for12 weeks. Total effective rate,the improvement of renal function,blood lipid,blood glucose and oxidative stress index were observed,and ADR was also observed. RESULTS：The total effective rate of experimental group was significantly higher than that of control group;there was statistical significance（P〈0.05）. The improvement of renal function,blood lipid,blood glucose and oxidative stress index in experimental group were significantly better than in control group;there was statistical significance（P〈0.05 or P〈0.01）. ADR were tolerable to all patients,and no severe ADR was found. CONCLUSIONS：A. moschatus capsule combined with Tripterygium glycosides tablets on DN is better than Tripterygium glycosides tablets alone in therapeutic efficacy and safety.